Imatinib Resistance in BCR-ABL1 Positive Leukemia Cell Lines
Author Information
Author(s): Quentmeier Hilmar, Eberth Sonja, Romani Julia, Zaborski Margarete, Drexler Hans G
Primary Institution: Leibniz-Institute DSMZ - German Collection of Microorganisms and Cell Cultures
Hypothesis
The study investigates the mechanisms of imatinib resistance in BCR-ABL1 positive leukemia cell lines.
Conclusion
The study identifies five BCR-ABL1 positive cell lines that exhibit imatinib resistance due to the activation of the PI3K/AKT1 pathway, rather than mutations in BCR-ABL1.
Supporting Evidence
- Five out of 19 BCR-ABL1 positive cell lines were resistant to imatinib-induced apoptosis.
- None of the resistant cell lines carried mutations in the kinase domain of BCR-ABL1.
- PI3K pathway inhibitors induced apoptosis in imatinib-resistant cells.
- The TKI-resistant cell line KCL-22 carries a PI3Kα E545G mutation.
- Inhibition of AKT1 induced apoptosis in TKI-resistant cell lines.
Takeaway
Some leukemia cells can resist a common treatment called imatinib, and this resistance is linked to a different pathway in the cells that keeps them alive.
Methodology
The study screened a panel of BCR-ABL1 positive cell lines for imatinib resistance using proliferation and apoptosis assays.
Limitations
The study does not explore all potential genetic alterations that could contribute to imatinib resistance.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website